Page 23 of 29

EN4.29 | Obstructive Sleep Apnea — SDL Guide (Part 2)

Systemic Complications and Differential Diagnosis

Untreated OSA is not merely a nuisance that disturbs the bed-partner — it is a significant chronic disease with well-documented cardiovascular, metabolic, and neurocognitive consequences. Understanding these complications is clinically important because they frequently present first in other specialty settings, and the ENT diagnosis of OSA may be the key that explains an otherwise refractory hypertension or an unexplained arrhythmia. The internist managing treatment-resistant hypertension, the cardiologist investigating recurrent atrial fibrillation, the endocrinologist treating metabolic syndrome — all may be seeing a patient whose underlying driver is undiagnosed OSA. The question 'Does your partner say you snore and stop breathing?' has the power to transform the management of a patient across multiple specialties.

The systemic consequences of OSA are mediated by two mechanisms: intermittent hypoxia (activates sympathetic nervous system, promotes oxidative stress, inflammation, endothelial dysfunction) and sleep fragmentation (activates the hypothalamic-pituitary-adrenal axis, impairs insulin sensitivity, promotes hunger hormone dysregulation).

Major systemic complications of OSA:
- Hypertension: present in 50–70% of patients with OSA; OSA is the most common identifiable cause of resistant hypertension (hypertension not controlled by three antihypertensives including a diuretic). Intermittent hypoxia chronically activates the sympathetic nervous system, raising vascular tone.
- Cardiovascular disease: 2–3× increased risk of coronary artery disease, heart failure, and stroke. Nocturnal hypoxia promotes atherosclerosis, arrhythmias (particularly atrial fibrillation), and sudden cardiac death.
- Type 2 diabetes and metabolic syndrome: intermittent hypoxia and sleep fragmentation impair insulin sensitivity; OSA is associated with a 2–3× increased risk of T2DM and metabolic syndrome independent of obesity.
- Atrial fibrillation: OSA is the most common comorbidity in patients with AF; treated OSA (CPAP) reduces AF recurrence after cardioversion.
- Excessive daytime somnolence and road traffic accidents: EDS in OSA impairs reaction times and vigilance equivalent to a blood alcohol concentration of 0.08%; professional drivers with untreated OSA have 2–7× increased accident risk.
- Cognitive impairment and dementia: chronic nocturnal hypoxia damages hippocampal neurons; OSA is associated with accelerated cognitive decline.
- Pulmonary hypertension: from repeated hypoxic pulmonary vasoconstriction.

Differential diagnosis — other causes of EDS:
- Narcolepsy: sudden onset of irresistible sleep (sleep attacks) + cataplexy (sudden muscle weakness triggered by emotion); not associated with snoring; PSG shows abnormal REM-onset sleep.
- Central sleep apnea: apnoeas WITHOUT obstructive effort (no respiratory effort during apnoea); associated with heart failure, opioid use, high altitude; treated differently from OSA.
- Idiopathic hypersomnia: excessive sleepiness despite adequate, non-fragmented nocturnal sleep; no apnoeas on PSG.
- Hypothyroidism: can cause EDS, weight gain, and macroglossia predisposing to OSA — always check TFTs in suspected OSA.

Principles of Management

The management of OSA is multi-modal and must address both the mechanical upper airway obstruction and the modifiable risk factors that increase its severity. No single treatment is universally effective, and management must be individualised based on AHI severity, OSA phenotype (anatomical vs neuromuscular vs positional), patient preference, and comorbidities. The management conversation must also address the systemic risk implications and driving safety.

Conservative measures (applicable to all patients):

Weight loss: the single most effective modifiable intervention for obese patients with OSA; a 10% reduction in body weight reduces AHI by approximately 26%. Even moderate weight loss improves OSA severity and systemic comorbidities. Diet, exercise, and in severe cases bariatric surgery all improve OSA.

Positional therapy: for positional OSA (predominantly supine), lateral sleeping position reduces AHI by 50–80% in some patients. Positional devices (vibrotactile alarms, shaped pillows, tennis-ball technique) enforce lateral sleeping.

Alcohol and sedative avoidance: alcohol relaxes pharyngeal dilator muscles and worsens OSA; stopping alcohol 4–6 hours before sleep is recommended.

Nasal obstruction treatment: addressing DNS, allergic rhinitis, or adenotonsillar hypertrophy improves nasal airflow, reduces mouth breathing, and modestly improves OSA — but rarely curative alone.

Pharmacological treatment of OSA:
There is no effective pharmacological treatment for OSA itself. Drug therapy is directed at comorbidities — antihypertensives, statins, HbA1c management in diabetes.

CPAP (Continuous Positive Airway Pressure):
The gold-standard treatment for moderate-severe OSA (AHI ≥15) and for mild OSA (AHI 5–15) with significant symptoms or cardiovascular comorbidity. A mask connected to a pressure generator provides a continuous column of air pressure that acts as a pneumatic splint, keeping the pharyngeal airway open throughout inspiration. Titrated to the minimum effective pressure (typically 5–15 cm H2O). CPAP eliminates apnoeas and oxygen desaturations immediately on the first night of use. Benefits: eliminates EDS, reduces hypertension (modest BP reduction), reduces cardiovascular risk, improves cognitive function. Compliance is the key challenge — 30–50% of patients are non-adherent long-term due to mask discomfort, claustrophobia, or noise.

Mandibular advancement device (MAD):
A custom-made oral appliance that holds the mandible and tongue in a forward (protruded) position during sleep, enlarging the posterior airway space. Less effective than CPAP for severe OSA but better tolerated; first-line for mild-moderate OSA in patients who cannot tolerate CPAP; useful for positional OSA.

Surgical options:
- Uvulopalatopharyngoplasty (UPPP): excision of the uvula, part of the soft palate, and redundant tonsillar/pharyngeal tissue; widens the oropharyngeal airway; effective in 40–50% of selected patients; not curative for severe OSA with retrognathia or hypopharyngeal collapse.
- Adenotonsillectomy: first-line surgical treatment for OSA in children with adenotonsillar hypertrophy; curative in the majority of paediatric OSA.
- Mandibular advancement surgery (maxillomandibular advancement, MMA): moves the mandible and maxilla forward, enlarging the entire pharyngeal airway; most effective surgical treatment for skeletal-based OSA; requires orthognathic surgery expertise.
- Hypoglossal nerve stimulation (HGNS): implantable device that stimulates the hypoglossal nerve (CN XII) during sleep, activating the genioglossus and preventing tongue-base collapse; indicated for moderate-severe OSA in patients intolerant of CPAP; not yet widely available in India.
- Nasal surgery (septoplasty, turbinate reduction, FESS for rhinosinusitis): treats nasal obstruction component; reduces overall upper airway resistance but usually insufficient as sole treatment for significant OSA.

Follow-up: compliance monitoring (CPAP machines record usage data) and repeat sleep study after weight loss, surgery, or CPAP titration.

Self-Assessment

Apply the full clinical and management framework from this module to this scenario before attempting the quiz. Use the AHI severity classification, the CPAP-first principle, and the systemic complication list to structure your answer:

A 40-year-old woman presents with a 3-year history of excessive daytime sleepiness (ESS 15), loud snoring, and two witnessed nocturnal apnoeic episodes per night per her husband. BMI is 32 kg/m². She has been on amlodipine 5 mg for hypertension for 2 years with incomplete control. STOP-BANG score is 5. Polysomnography shows AHI of 22, minimum SpO2 of 84%.

Classify the OSA severity. List two systemic complications she is at risk for. What is the first-line treatment? What lifestyle modification is the single most impactful? If she refuses CPAP, what is the alternative device? Should she be restricted from driving?